BUSINESS INSIGHTS : The latest news, analysis, and trends about protection and care

Jul 19, 2018,  by Allianz Partners Business Insights

Prostate cancer: software accurately measures patient bone metastases

US researchers have demonstrated the effectiveness of Swedish software in measuring and evaluating bone metastases that develop in prostate cancer sufferers. The programme promises to be more reliable and much faster than previous techniques and will provide accurate information on the survival time of patients as well as improved treatment.


Software developed by a Swedish company has demonstrated in trials that it can automatically measure bone metastases in patients with advanced prostate cancer. Developed by the company EXINI Diagnostics, the automated Bone Scan Index (aBSI) was shown in a study conducted by researchers to be both accurate and fast. The results were published in the Journal of the American Medical Association in May. 


Analysis of medical results


Based at the Duke Cancer Institute (USA), the specialists used the aBSI to assess 721 patients suffering from advanced prostate cancer. The study’s authors found that the software could scan the results of radiographic studies and accurately quantify the degree of bone metastases, as reported by Health Data Management.

Such data is vital to treatment as it enables the correct course of action to be selected for each case, and also identifies patients’ chances of survival. The Swedish programme provided this information in a matter of seconds, whereas existing procedures can take several hours, explained Andrew Armstrong, the lead author of the study.


More effective than traditional methods 


The aBSI’s calculations were also found to be more accurate, regardless of the extent of bone metastases in patients. The researchers believe the software would be more useful than the protocols commonly used, which are based on scanners, IRM, and imaging techniques used in nuclear medicine and enabling manual and visual calculation. These protocols have two drawbacks: the time they take and their subjective nature.

“It’s important for doctors, patients and cancer researchers to have a reliable bone marker to better treat patients and prevent or delay bone metastases,” added Armstrong.


Allianz Partners

Linked Topic
About Allianz Partners Business Insights